Journalists from Citeline's In Vivo publication and guests discuss in depth topics relating to the global biotech and pharma industry.

In Vivo Podcasts From Citeline

Accenture's Petra Jantzer on M&A trends and what it means for execs

Panthera Biopartners Discuss The SMO Strategy

Inside medical research charity LifeArc, with CEO Melanie Lee

In Vivo executive editor Lucie Ellis-Taitt and Infex CEO Peter Jackson explore the current state of antimicrobial resistance in the UK, and worldwide. They discuss the potential of a new “Netflix” style subscription model in the UK for antibiotic reimbursement, as well as future challenges for biotechs in the anti-infectives space.

Will A ‘Netflix’ Model Solve Antibiotic Reimbursement Challenges And Spur R&D?

9xchange CEO Anat Naschitz and Benevolent AI's Matthew Fujisawa spoke with In Vivo about how they are trying to make selling and buying pharma assets more efficient through a digital marketplace and AI.

A Digital Marketplace Aims To Make Asset Acquisition Frictionless

What if we could train AI to understand how stem cells become any cell type in the human body? In this episode of the In Vivo Podcast, host David Wild sits down with Micha Breakstone (CEO & Co-founder) and Samantha Dale Strasser (VP of Strategy) from Somite.AI to explore how their company is using foundation models to revolutionize cell therapy development.
 
Somite has pioneered a breakthrough approach that generates cell differentiation data at 1000x the efficiency of traditional methods using proprietary hydrogel capsule technology. By capturing millions of trajectories showing how cells respond to signals over time, they're building DeltaStem—a foundation model that could do for developmental biology what AlphaFold did for protein structure prediction.
 
Topics covered:
 
- How bringing cells to signals (rather than signals to cells) unlocks exponential scale
- Why wet lab innovation is just as critical as AI models
- Manufacturing optimization: improving purity, reducing variability, and cutting costs
- From beta cells for diabetes to brown fat for metabolic disease—the therapeutic pipeline
- Why even AI experts underestimate what's coming in the next decade
- Lessons from building biotech companies from academic concepts to commercial ventures
 
Whether you're in pharma, biotech, AI or just fascinated by the intersection of technology and human biology, this conversation offers a grounded look at how foundation models are moving from hype to real therapeutic impact.

Decoding Cell Differentiation: How AI Foundation Models Are Reshaping Regenerative Medicine

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.